On Sept. 15, 2022, Gilead Sciences announced updates to the World Health Organizationﾒs Therapeutics and COVID-19: living guideline, which conditionally recommended Vekluryﾮ (remdesivir) for the treatment of patients with severe COVID-19 and continued to conditionally recommend Veklury in those with non-severe COVID-19 at the highest risk of hospitalization.